Zai Lab LTD ZLAB
We take great care to ensure that the data presented and summarized in this overview for Zai Lab Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZLAB
View all-
Capital World Investors Los Angeles, CA6.01MShares$214 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X03.81MShares$136 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.65MShares$130 Million0.03% of portfolio
-
Clearbridge Investments, LLC New York, NY3.28MShares$117 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY3.14MShares$112 Million1.86% of portfolio
-
Principal Financial Group Inc Des Moines, IA2.88MShares$103 Million0.06% of portfolio
-
Morgan Stanley New York, NY2.63MShares$93.9 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.27MShares$80.9 Million0.01% of portfolio
-
Mirae Asset Global Investments Co., Ltd.2.13MShares$76 Million0.21% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M1.88MShares$67.2 Million0.1% of portfolio
Latest Institutional Activity in ZLAB
Top Purchases
Top Sells
About ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Insider Transactions at ZLAB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 02
2025
|
Du Ying Chairperson & CEO |
SELL
Open market or private sale
|
Direct |
7,072
-1.3%
|
$247,520
$35.23 P/Share
|
Jul 01
2025
|
Du Ying Chairperson & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+3.2%
|
-
|
Jun 30
2025
|
Du Ying Chairperson & CEO |
SELL
Open market or private sale
|
Direct |
6,918
-1.3%
|
$242,130
$35.52 P/Share
|
Jun 27
2025
|
Du Ying Chairperson & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,970
+3.26%
|
-
|
Jun 26
2025
|
Yajing Chen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,675
-11.3%
|
$96,300
$36.13 P/Share
|
Jun 26
2025
|
Du Ying Chairperson & CEO |
SELL
Open market or private sale
|
Direct |
23,669
-4.39%
|
$852,084
$36.13 P/Share
|
Jun 26
2025
|
Frazor Titus Edmondson Iii Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,877
-13.07%
|
$211,572
$36.13 P/Share
|
Jun 25
2025
|
Yajing Chen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+20.88%
|
-
|
Jun 25
2025
|
Du Ying Chairperson & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
58,800
+9.84%
|
-
|
Jun 25
2025
|
Frazor Titus Edmondson Iii Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,600
+24.51%
|
-
|
Jun 20
2025
|
William Lis |
SELL
Open market or private sale
|
Direct |
13,814
-28.24%
|
$483,490
$35.67 P/Share
|
Jun 18
2025
|
Nisa Leung |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+12.78%
|
-
|
Jun 18
2025
|
William Lis |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+18.13%
|
-
|
Jun 18
2025
|
John D Diekman |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+9.79%
|
-
|
Jun 18
2025
|
Richard Gaynor |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+16.48%
|
-
|
Jun 18
2025
|
Scott W Morrison |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+23.88%
|
-
|
Jun 18
2025
|
Leon O Moulder Jr |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+12.98%
|
-
|
Jun 18
2025
|
Michel Vounatsos |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+17.68%
|
-
|
Jun 18
2025
|
Peter Wirth |
BUY
Grant, award, or other acquisition
|
Direct |
10,831
+2.68%
|
-
|
Jun 02
2025
|
Yajing Chen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,618
-35.56%
|
$288,540
$30.0 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 678K shares |
---|---|
Grant, award, or other acquisition | 86.6K shares |
Open market or private sale | 588K shares |
---|---|
Bona fide gift | 614K shares |
Sale (or disposition) back to the issuer | 21.3K shares |